Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 6/20 | 0.37 |
| ▸ | HTR2B | P41595 | 5/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19370610 | 0.82 | OPRM1 (0.40) | CDADDB1CRBN | |
| SCHEMBL30963361 | 0.80 | CDA (0.40) | CDADDB1CRBN | |
| SCHEMBL1810703 | 0.80 | PARP1 (0.37) | HTR2CHTR2BDDB1CRBNTP53 | |
| SCHEMBL994623 | 0.78 | HTR2C (0.40) | HTR2CHTR2BTP53HTR2AACVRL1 | |
| SCHEMBL30830825 | 0.76 | DDB1 (0.41) | CDADDB1CRBN | |
| SCHEMBL30178303 | 0.74 | HTR2C (0.49) | HTR2CHTR2BHTR2APARP1 | |
| SCHEMBL651023 | 0.74 | HTR2C (0.49) | HTR2CHTR2BHTR2APARP1 | |
| SCHEMBL13656015 | 0.74 | TP53 (0.33) | HTR2CHTR2BTP53ACVRL1ACVR1 | |
| SCHEMBL13655678 | 0.74 | HTR2C (0.34) | HTR2CHTR2BTP53HTR2AACVRL1 | |
| SCHEMBL726957 | 0.74 | HTR2C (0.40) | HTR2CHTR2BTP53HTR2AFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-12454521-B2 | Targeted protein degradation | C4 THERAPEUTICS, INC. | 2025-10-28 | — | — | US | disclosed |
| CN-119630644-A | Bifunctional compounds containing pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway | 霖康疗法公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119630651-A | Bifunctional compounds containing substituted pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway | 霖康疗法公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20220372016-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-11-24 | — | — | US | disclosed |
| EP-3897631-A1 | TARGETED PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113453679-A | Targeted protein degradation | C4医药公司 | 2021-09-28 | — | — | CN | disclosed |
| WO-2020132561-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| EP-2208726-B1 | Cyclic amide derivatives, and their production and use as antithrombotic agents | TAKEDA PHARMACEUTICAL (JP) | 2014-08-20 | — | — | EP | disclosed |
| US-8697865-B2 | Cyclic amide derivative, and its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-15 | — | — | US | disclosed |
| EP-2208726-A1 | Cyclic amide derivatives, and their production and use as antithrombotic agents | Takeda Pharmaceutical Company Limited (JP) | 2010-07-21 | — | — | EP | disclosed |
| US-7745623-B2 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20100160629-A1 | CYCLIC AMIDE DERIVATIVE, AND ITS PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20080255362-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080255352-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20070244118-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-10-18 | — | — | US | disclosed |
| US-4514403-A | NONHABIT-FORMING CENTRALLY ACTING ANALGESIC | YOSHITOMI PHARMACEUTICAL INDUSTRIES LTD. (JP) | 1985-04-30 | — | — | US | disclosed |
| EP-0047990-B1 | HYDROURACIL COMPOUNDS | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1984-01-25 | — | — | EP | disclosed |
| EP-0047990-A1 | Hydrouracil compounds | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1982-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255352-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | JAK2, CNR1, F2 | CDA 4720/4885HTR2C 514/4885HTR2B 1395/4885 |
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | PSMC3, PSMA6, ADRM1 | CDA 4326/4885HTR2C 2045/4885HTR2B 4296/4885 |
| US-20220372016-A1 | TARGETED PROTEIN DEGRADATION | STUB1, MDM2, UBE3A | CDA 3172/4885HTR2C 3639/4885HTR2B 3739/4885 |
| US-20100160629-A1 | CYCLIC AMIDE DERIVATIVE, AND ITS PRODUCTION AND USE | CNR1, CNR2, ARG1 | CDA 4111/4885HTR2C 529/4885HTR2B 1012/4885 |
| US-12454521-B2 | Targeted protein degradation | STUB1, MDM2, UBE3A | CDA 3172/4885HTR2C 3639/4885HTR2B 3739/4885 |
| US-20070244118-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | JAK2, CNR1, CNR2 | CDA 4760/4885HTR2C 528/4885HTR2B 1331/4885 |
| US-20080255362-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | JAK2, CNR1, F2 | CDA 4720/4885HTR2C 514/4885HTR2B 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.